Ocugen
Biopharmaceutical company developing gene therapies for blindness diseases.
Last updated September 11, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Ocugen is a biopharmaceutical company that describes itself as redefining the future of vision through gene therapies, with a first-in-class modifier gene therapy platform aimed at inherited retinal diseases and blindness diseases. Its leadership states that Ocugen was co-founded in 2013 by Shankar Musunuri, who serves as Chairman of the Board, CEO and Co-founder. The company reports clinical activity including a Phase 3 registrational trial of OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, and states that the U.S. Food and Drug Administration granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation for that condition. Ocugen lists Bharat Biotech and CanSinoBIO among its partners.
History
Ocugen's leadership states that the company was co-founded in 2013 by Shankar Musunuri, who serves as Chairman of the Board, CEO and Co-founder. The company describes itself as a patient-centric biotechnology company redefining the future of vision through gene therapies, with a first-in-class modifier gene therapy platform intended to address inherited retinal diseases and blindness diseases. It reports a Phase 3 registrational trial of OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, and states that the U.S. Food and Drug Administration granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation for that condition. Ocugen also lists Bharat Biotech and CanSinoBIO among its partners.
Products and positioning
Patient-centric biotechnology focused on gene therapies for blindness diseases.
OCU410 modifier gene therapy
Modifier gene therapy in a Phase 3 registrational trial for geographic atrophy secondary to dry age-related macular degeneration; granted RMAT designation by the U.S. Food and Drug Administration for that condition.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ocugen · Editorial policy · How profiles are compiled